Impact of the major BCR-ABL1 transcript type on clinical and biological parameters and molecular response in patients with chronic myeloid leukemia

Burmeister, 2008, A multiplex PCR for improved detection of typical and atypical BCR–ABL fusion transcripts, Leuk Res, 32, 579, 10.1016/j.leukres.2007.08.017 Kantarjian, 2012, Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience, Blood, 119, 1981, 10.1182/blood-2011-08-358135 Baccarani, 2013, European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013, Blood, 122, 872, 10.1182/blood-2013-05-501569 Ercaliskan, 2018, The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia, Cancer, 124, 3806, 10.1002/cncr.31408 Baccarani, 2019, The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview, Leukemia, 33, 1173, 10.1038/s41375-018-0341-4 Pfirrmann, 2017, No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib, J Cancer Res Clin Oncol, 143, 843, 10.1007/s00432-016-2321-2 Sharma, 2010, Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts, Ann Hematol, 89, 241, 10.1007/s00277-009-0822-7 Lucas, 2009, Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript, Haematologica, 94, 1362, 10.3324/haematol.2009.009134 Jain, 2016, Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors, Blood, 127, 1269, 10.1182/blood-2015-10-674242 Castagnetti, 2017, The BCR-ABL1 transcript type influences response and outcome in P hiladelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib, Am J Hematol, 92, 797, 10.1002/ajh.24774 Kagita, 2018, Assessment of BCR-ABL1 fusion transcripts and their association with response to imatinib treatment in chronic myeloid leukemia patients, Indian J Med Paediatr Oncol, 39, 165, 10.4103/ijmpo.ijmpo_80_17 Deb, 2014, Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate, Indian J Med Paediatr Oncol, 35, 26, 10.4103/0971-5851.133707 Polampalli, 2008, Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts, Genet Mol Res, 7, 1138, 10.4238/vol7-4gmr485 Al-Achkar, 2016, Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients, J BUON, 21, 444 Hanfstein, 2014, Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib, Haematologica, 99, 1441, 10.3324/haematol.2013.096537